ImmunityBio (IBRX) Short-term Investments (2015 - 2026)

ImmunityBio (IBRX) has 12 years of Short-term Investments data on file, last reported at $175.7 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $175.7 million, up 18770.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $175.7 million (up 18770.57% YoY), and the FY2025 annual result was $154.5 million, up 2321.0% from the prior year.
• Short-term Investments grew to $175.7 million in Q1 2026 per IBRX's latest filing, from $154.5 million in the prior quarter.
• Over five years, Short-term Investments peaked at $197.6 million in Q3 2025 and troughed at $931000.0 in Q1 2025.
• A 5-year average of $52.9 million and a median of $16.0 million in 2025 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2026: Short-term Investments slumped 98.21% in 2023, then surged 18770.57% in 2026.
• A 5-year view of Short-term Investments shows it stood at $2.5 million in 2022, then tumbled by 60.32% to $1.0 million in 2023, then jumped by 532.41% to $6.4 million in 2024, then jumped by 2321.0% to $154.5 million in 2025, then gained by 13.72% to $175.7 million in 2026.
• Business Quant data shows IBRX's Short-term Investments at $175.7 million in Q1 2026, $154.5 million in Q4 2025, and $197.6 million in Q3 2025.